
Liver Cancer Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application
Description
Liver Cancer Drug Market Summary
and Market Overview
Liver cancer drugs encompass targeted therapies, immunotherapies, and chemotherapies to manage hepatocellular carcinoma (HCC), with 900,000 new cases in 2020, 70% in Asia due to hepatitis B and C prevalence. The market is driven by rising liver cancer incidence, with 10% of 325 million hepatitis patients progressing to HCC, and breakthroughs in immunotherapy, such as atezolizumab plus bevacizumab, extending median survival to 19 months. Early diagnosis initiatives, aging populations, and high viral hepatitis burden fuel demand. The global liver cancer drug market is estimated at USD 2.5-4.0 billion in 2025, with a CAGR of 15%-20% through 2030.
Regional Market Trends
North America: The U.S. leads with advanced immunotherapy adoption, while Canada focuses on hepatitis screening.
Europe: Germany, France, and the UK drive growth with robust oncology programs.
Asia Pacific: China and India see high demand due to hepatitis prevalence, with Japan emphasizing targeted therapies.
Rest of the World: Brazil expands HCC treatment access, while Africa addresses hepatitis-related cancers.
Application Analysis
Targeted Therapy: Expected growth of 15.5%-20.5%, driven by sorafenib and lenvatinib. Trends focus on multi-kinase inhibitors.
Immunotherapy: Projected growth of 16.0%-21.0%, favored for long-term survival. Advances emphasize PD-1/PD-L1 inhibitors.
Chemotherapy: Anticipated growth of 14.0%-19.0%, used in advanced cases. Trends highlight combination regimens.
Others: Expected growth of 13.5%-18.5%, covering ablation therapies. Developments prioritize minimally invasive options.
Key Market Players
Bayer: Offers sorafenib for HCC.
Roche: Develops atezolizumab for immunotherapy.
Merck: Provides PD-1 inhibitors for liver cancer.
Bristol-Myers Squibb: Focuses on immunotherapy combinations.
Eisai: Specializes in lenvatinib for targeted therapy.
Porter’s Five Forces Analysis
Threat of New Entrants: Low, due to high R&D costs and regulatory barriers.
Threat of Substitutes: Moderate, with surgical options competing, but drugs are primary for advanced HCC.
Bargaining Power of Buyers: Moderate, as hospitals seek cost-effective therapies, but specialized drugs limit choices.
Bargaining Power of Suppliers: Low, with multiple providers of active ingredients.
Competitive Rivalry: High, with players competing on efficacy and survival outcomes.
Market Opportunities and Challenges
Opportunities:
Addressing liver cancer, with 900,000 new cases in 2020.
Leveraging immunotherapy, extending survival to 19 months.
Managing hepatitis, affecting 325 million people.
Supporting early diagnosis initiatives for HCC.
Meeting demand in Asia, with 70% of cases.
Expanding access to generics in low-income regions.
Challenges:
High costs of immunotherapies limiting access.
Regulatory delays for novel drugs.
Limited screening infrastructure in developing regions.
Competition from ablation and surgical treatments.
Side effects requiring patient monitoring.
and Market Overview
Liver cancer drugs encompass targeted therapies, immunotherapies, and chemotherapies to manage hepatocellular carcinoma (HCC), with 900,000 new cases in 2020, 70% in Asia due to hepatitis B and C prevalence. The market is driven by rising liver cancer incidence, with 10% of 325 million hepatitis patients progressing to HCC, and breakthroughs in immunotherapy, such as atezolizumab plus bevacizumab, extending median survival to 19 months. Early diagnosis initiatives, aging populations, and high viral hepatitis burden fuel demand. The global liver cancer drug market is estimated at USD 2.5-4.0 billion in 2025, with a CAGR of 15%-20% through 2030.
Regional Market Trends
North America: The U.S. leads with advanced immunotherapy adoption, while Canada focuses on hepatitis screening.
Europe: Germany, France, and the UK drive growth with robust oncology programs.
Asia Pacific: China and India see high demand due to hepatitis prevalence, with Japan emphasizing targeted therapies.
Rest of the World: Brazil expands HCC treatment access, while Africa addresses hepatitis-related cancers.
Application Analysis
Targeted Therapy: Expected growth of 15.5%-20.5%, driven by sorafenib and lenvatinib. Trends focus on multi-kinase inhibitors.
Immunotherapy: Projected growth of 16.0%-21.0%, favored for long-term survival. Advances emphasize PD-1/PD-L1 inhibitors.
Chemotherapy: Anticipated growth of 14.0%-19.0%, used in advanced cases. Trends highlight combination regimens.
Others: Expected growth of 13.5%-18.5%, covering ablation therapies. Developments prioritize minimally invasive options.
Key Market Players
Bayer: Offers sorafenib for HCC.
Roche: Develops atezolizumab for immunotherapy.
Merck: Provides PD-1 inhibitors for liver cancer.
Bristol-Myers Squibb: Focuses on immunotherapy combinations.
Eisai: Specializes in lenvatinib for targeted therapy.
Porter’s Five Forces Analysis
Threat of New Entrants: Low, due to high R&D costs and regulatory barriers.
Threat of Substitutes: Moderate, with surgical options competing, but drugs are primary for advanced HCC.
Bargaining Power of Buyers: Moderate, as hospitals seek cost-effective therapies, but specialized drugs limit choices.
Bargaining Power of Suppliers: Low, with multiple providers of active ingredients.
Competitive Rivalry: High, with players competing on efficacy and survival outcomes.
Market Opportunities and Challenges
Opportunities:
Addressing liver cancer, with 900,000 new cases in 2020.
Leveraging immunotherapy, extending survival to 19 months.
Managing hepatitis, affecting 325 million people.
Supporting early diagnosis initiatives for HCC.
Meeting demand in Asia, with 70% of cases.
Expanding access to generics in low-income regions.
Challenges:
High costs of immunotherapies limiting access.
Regulatory delays for novel drugs.
Limited screening infrastructure in developing regions.
Competition from ablation and surgical treatments.
Side effects requiring patient monitoring.
Table of Contents
87 Pages
- Chapter 1 Executive Summary
- Chapter 2 Abbreviation and Acronyms
- Chapter 3 Preface
- 3.1 Research Scope
- 3.2 Research Sources
- 3.2.1 Data Sources
- 3.2.2 Assumptions
- 3.3 Research Method
- Chapter Four Market Landscape
- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users
- Chapter 5 Market Trend Analysis
- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats
- Chapter 6 Industry Chain Analysis
- 6.1 Upstream/Suppliers Analysis
- 6.2 Liver Cancer Drug Analysis
- 6.2.1 Technology Analysis
- 6.2.2 Cost Analysis
- 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users
- Chapter 7 Latest Market Dynamics
- 7.1 Latest News
- 7.2 Merger and Acquisition
- 7.3 Planned/Future Project
- 7.4 Policy Dynamics
- Chapter 8 Historical and Forecast Liver Cancer Drug Market in North America (2020-2030)
- 8.1 Liver Cancer Drug Market Size
- 8.2 Liver Cancer Drug Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Liver Cancer Drug Market Size by Type
- 8.5 Key Countries Analysis
- 8.5.1 United States
- 8.5.2 Canada
- 8.5.3 Mexico
- Chapter 9 Historical and Forecast Liver Cancer Drug Market in South America (2020-2030)
- 9.1 Liver Cancer Drug Market Size
- 9.2 Liver Cancer Drug Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Liver Cancer Drug Market Size by Type
- 9.5 Key Countries Analysis
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Chile
- 9.5.4 Peru
- Chapter 10 Historical and Forecast Liver Cancer Drug Market in Asia & Pacific (2020-2030)
- 10.1 Liver Cancer Drug Market Size
- 10.2 Liver Cancer Drug Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Liver Cancer Drug Market Size by Type
- 10.5 Key Countries Analysis
- 10.5.1 China
- 10.5.2 India
- 10.5.3 Japan
- 10.5.4 South Korea
- 10.5.5 Southest Asia
- 10.5.6 Australia
- Chapter 11 Historical and Forecast Liver Cancer Drug Market in Europe (2020-2030)
- 11.1 Liver Cancer Drug Market Size
- 11.2 Liver Cancer Drug Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Liver Cancer Drug Market Size by Type
- 11.5 Key Countries Analysis
- 11.5.1 Germany
- 11.5.2 France
- 11.5.3 United Kingdom
- 11.5.4 Italy
- 11.5.5 Spain
- 11.5.6 Belgium
- 11.5.7 Netherlands
- 11.5.8 Austria
- 11.5.9 Poland
- 11.5.10 Russia
- Chapter 12 Historical and Forecast Liver Cancer Drug Market in MEA (2020-2030)
- 12.1 Liver Cancer Drug Market Size
- 12.2 Liver Cancer Drug Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Liver Cancer Drug Market Size by Type
- 12.5 Key Countries Analysis
- 12.5.1 Egypt
- 12.5.2 Israel
- 12.5.3 South Africa
- 12.5.4 Gulf Cooperation Council Countries
- 12.5.5 Turkey
- Chapter 13 Summary For Global Liver Cancer Drug Market (2020-2025)
- 13.1 Liver Cancer Drug Market Size
- 13.2 Liver Cancer Drug Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Liver Cancer Drug Market Size by Type
- Chapter 14 Global Liver Cancer Drug Market Forecast (2025-2030)
- 14.1 Liver Cancer Drug Market Size Forecast
- 14.2 Liver Cancer Drug Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Liver Cancer Drug Type Forecast
- Chapter 15 Analysis of Global Key Vendors
- 15.1 Bayer
- 15.1.1 Company Profile
- 15.1.2 Main Business and Liver Cancer Drug Information
- 15.1.3 SWOT Analysis of Bayer
- 15.1.4 Bayer Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Roche
- 15.2.1 Company Profile
- 15.2.2 Main Business and Liver Cancer Drug Information
- 15.2.3 SWOT Analysis of Roche
- 15.2.4 Roche Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Merck
- 15.3.1 Company Profile
- 15.3.2 Main Business and Liver Cancer Drug Information
- 15.3.3 SWOT Analysis of Merck
- 15.3.4 Merck Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 Bristol-Myers Squibb
- 15.4.1 Company Profile
- 15.4.2 Main Business and Liver Cancer Drug Information
- 15.4.3 SWOT Analysis of Bristol-Myers Squibb
- 15.4.4 Bristol-Myers Squibb Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.5 Eisai
- 15.5.1 Company Profile
- 15.5.2 Main Business and Liver Cancer Drug Information
- 15.5.3 SWOT Analysis of Eisai
- 15.5.4 Eisai Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.6 Exelixis
- 15.6.1 Company Profile
- 15.6.2 Main Business and Liver Cancer Drug Information
- 15.6.3 SWOT Analysis of Exelixis
- 15.6.4 Exelixis Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
- Please ask for sample pages for full companies list
- Tables and Figures
- Table Abbreviation and Acronyms
- Table Research Scope of Liver Cancer Drug Report
- Table Data Sources of Liver Cancer Drug Report
- Table Major Assumptions of Liver Cancer Drug Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure Liver Cancer Drug Picture
- Table Liver Cancer Drug Classification
- Table Liver Cancer Drug Applications
- Table Drivers of Liver Cancer Drug Market
- Table Restraints of Liver Cancer Drug Market
- Table Opportunities of Liver Cancer Drug Market
- Table Threats of Liver Cancer Drug Market
- Table Covid-19 Impact For Liver Cancer Drug Market
- Table Raw Materials Suppliers
- Table Different Production Methods of Liver Cancer Drug
- Table Cost Structure Analysis of Liver Cancer Drug
- Table Key End Users
- Table Latest News of Liver Cancer Drug Market
- Table Merger and Acquisition
- Table Planned/Future Project of Liver Cancer Drug Market
- Table Policy of Liver Cancer Drug Market
- Table 2020-2030 North America Liver Cancer Drug Market Size
- Figure 2020-2030 North America Liver Cancer Drug Market Size and CAGR
- Table 2020-2030 North America Liver Cancer Drug Market Size by Application
- Table 2020-2025 North America Liver Cancer Drug Key Players Revenue
- Table 2020-2025 North America Liver Cancer Drug Key Players Market Share
- Table 2020-2030 North America Liver Cancer Drug Market Size by Type
- Table 2020-2030 United States Liver Cancer Drug Market Size
- Table 2020-2030 Canada Liver Cancer Drug Market Size
- Table 2020-2030 Mexico Liver Cancer Drug Market Size
- Table 2020-2030 South America Liver Cancer Drug Market Size
- Figure 2020-2030 South America Liver Cancer Drug Market Size and CAGR
- Table 2020-2030 South America Liver Cancer Drug Market Size by Application
- Table 2020-2025 South America Liver Cancer Drug Key Players Revenue
- Table 2020-2025 South America Liver Cancer Drug Key Players Market Share
- Table 2020-2030 South America Liver Cancer Drug Market Size by Type
- Table 2020-2030 Brazil Liver Cancer Drug Market Size
- Table 2020-2030 Argentina Liver Cancer Drug Market Size
- Table 2020-2030 Chile Liver Cancer Drug Market Size
- Table 2020-2030 Peru Liver Cancer Drug Market Size
- Table 2020-2030 Asia & Pacific Liver Cancer Drug Market Size
- Figure 2020-2030 Asia & Pacific Liver Cancer Drug Market Size and CAGR
- Table 2020-2030 Asia & Pacific Liver Cancer Drug Market Size by Application
- Table 2020-2025 Asia & Pacific Liver Cancer Drug Key Players Revenue
- Table 2020-2025 Asia & Pacific Liver Cancer Drug Key Players Market Share
- Table 2020-2030 Asia & Pacific Liver Cancer Drug Market Size by Type
- Table 2020-2030 China Liver Cancer Drug Market Size
- Table 2020-2030 India Liver Cancer Drug Market Size
- Table 2020-2030 Japan Liver Cancer Drug Market Size
- Table 2020-2030 South Korea Liver Cancer Drug Market Size
- Table 2020-2030 Southeast Asia Liver Cancer Drug Market Size
- Table 2020-2030 Australia Liver Cancer Drug Market Size
- Table 2020-2030 Europe Liver Cancer Drug Market Size
- Figure 2020-2030 Europe Liver Cancer Drug Market Size and CAGR
- Table 2020-2030 Europe Liver Cancer Drug Market Size by Application
- Table 2020-2025 Europe Liver Cancer Drug Key Players Revenue
- Table 2020-2025 Europe Liver Cancer Drug Key Players Market Share
- Table 2020-2030 Europe Liver Cancer Drug Market Size by Type
- Table 2020-2030 Germany Liver Cancer Drug Market Size
- Table 2020-2030 France Liver Cancer Drug Market Size
- Table 2020-2030 United Kingdom Liver Cancer Drug Market Size
- Table 2020-2030 Italy Liver Cancer Drug Market Size
- Table 2020-2030 Spain Liver Cancer Drug Market Size
- Table 2020-2030 Belgium Liver Cancer Drug Market Size
- Table 2020-2030 Netherlands Liver Cancer Drug Market Size
- Table 2020-2030 Austria Liver Cancer Drug Market Size
- Table 2020-2030 Poland Liver Cancer Drug Market Size
- Table 2020-2030 Russia Liver Cancer Drug Market Size
- Table 2020-2030 MEA Liver Cancer Drug Market Size
- Figure 2020-2030 MEA Liver Cancer Drug Market Size and CAGR
- Table 2020-2030 MEA Liver Cancer Drug Market Size by Application
- Table 2020-2025 MEA Liver Cancer Drug Key Players Revenue
- Table 2020-2025 MEA Liver Cancer Drug Key Players Market Share
- Table 2020-2030 MEA Liver Cancer Drug Market Size by Type
- Table 2020-2030 Egypt Liver Cancer Drug Market Size
- Table 2020-2030 Israel Liver Cancer Drug Market Size
- Table 2020-2030 South Africa Liver Cancer Drug Market Size
- Table 2020-2030 Gulf Cooperation Council Countries Liver Cancer Drug Market Size
- Table 2020-2030 Turkey Liver Cancer Drug Market Size
- Table 2020-2025 Global Liver Cancer Drug Market Size by Region
- Table 2020-2025 Global Liver Cancer Drug Market Size Share by Region
- Table 2020-2025 Global Liver Cancer Drug Market Size by Application
- Table 2020-2025 Global Liver Cancer Drug Market Share by Application
- Table 2020-2025 Global Liver Cancer Drug Key Vendors Revenue
- Figure 2020-2025 Global Liver Cancer Drug Market Size and Growth Rate
- Table 2020-2025 Global Liver Cancer Drug Key Vendors Market Share
- Table 2020-2025 Global Liver Cancer Drug Market Size by Type
- Table 2020-2025 Global Liver Cancer Drug Market Share by Type
- Table 2025-2030 Global Liver Cancer Drug Market Size by Region
- Table 2025-2030 Global Liver Cancer Drug Market Size Share by Region
- Table 2025-2030 Global Liver Cancer Drug Market Size by Application
- Table 2025-2030 Global Liver Cancer Drug Market Share by Application
- Table 2025-2030 Global Liver Cancer Drug Key Vendors Revenue
- Figure 2025-2030 Global Liver Cancer Drug Market Size and Growth Rate
- Table 2025-2030 Global Liver Cancer Drug Key Vendors Market Share
- Table 2025-2030 Global Liver Cancer Drug Market Size by Type
- Table 2025-2030 Liver Cancer Drug Global Market Share by Type
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.